Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Atkinson

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Genome Announcements|May 20, 2017
Genome Sequence of Human Papillomavirus 23 Strain HPV-23/Lancaster/2015Kate V Atkinson, Lisa A Bishop, Glenn Rhodes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2016
Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 studyG V Long, V Atkinson, P A Ascierto, et al.
Nature Communications|December 22, 2018
Revealing internal flow behaviour in arc welding and additive manufacturing of metalsLee Aucott, Hongbiao Dong, Wajira Mirihanage, et al.
British Journal of Cancer|April 29, 2016
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyS Bowyer, P Prithviraj, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanomaY J L Jansen, E A Rozeman, R Mason, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2020
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy<sup>☆</sup>C N Owen, A N Shoushtari, D Chauhan, et al.
ESMO Open|February 27, 2026
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitorsE S M van Aken, S M O'Cathail, A K Gandhi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 6, 2023
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemiaS H Cass, J W D Tobin, Y D Seo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2025
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanomaR V Rawson, N G Maher, A M Menzies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2022
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyF Dimitriou, K Namikawa, I L M Reijers, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Genome Announcements|May 20, 2017
Genome Sequence of Human Papillomavirus 23 Strain HPV-23/Lancaster/2015Kate V Atkinson, Lisa A Bishop, Glenn Rhodes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2016
Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 studyG V Long, V Atkinson, P A Ascierto, et al.
Nature Communications|December 22, 2018
Revealing internal flow behaviour in arc welding and additive manufacturing of metalsLee Aucott, Hongbiao Dong, Wajira Mirihanage, et al.
British Journal of Cancer|April 29, 2016
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyS Bowyer, P Prithviraj, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanomaY J L Jansen, E A Rozeman, R Mason, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2020
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy<sup>☆</sup>C N Owen, A N Shoushtari, D Chauhan, et al.
ESMO Open|February 27, 2026
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitorsE S M van Aken, S M O'Cathail, A K Gandhi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 6, 2023
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemiaS H Cass, J W D Tobin, Y D Seo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2025
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanomaR V Rawson, N G Maher, A M Menzies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2022
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyF Dimitriou, K Namikawa, I L M Reijers, et al.
Pageof 3